TrialThe lancet. Diabetes & endocrinology2017

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.

Vanita R Aroda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.